Compare Medpace Holdings Inc (MEDP) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs QUALCOMM, Inc. — how do they compare? Medpace Holdings Inc trades at $601.26 (market cap $16.90B), while QUALCOMM, Inc. trades at $162.14 (market cap $170.81B). The key difference: QUALCOMM, Inc. is far larger — about 10.1× Medpace Holdings Inc's market cap, and QUALCOMM, Inc. pays a 2.26% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | QCOM | |
|---|---|---|
Market Cap | $16.90B | $170.81B |
Sector | Technology | Technology |
52-Week High | $620.59 | $251.10 |
52-Week Low | $393.42 | $124.07 |
Enterprise Value | $16.52B | $177.78B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Qualcomm (QCOM) trades at $162.17, down 3.39% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong revenue of $44.28B in 2025 but saw net income decline to $5.54B, reflecting margin pressures. Recent news highlights Qualcomm's AI and data center expansion efforts, including the 'Dragonfly' AI platform announcement at COMPUTEX 2026, while facing increased competition from Nvidia in the PC chip market.
The outlook remains balanced with a consensus price target of $200.56 suggesting 24% upside, but near-term headwinds include smartphone market softness and margin compression. Long-term growth drivers in automotive and AI inference markets provide opportunity, though execution risks and competitive threats from chip rivals pose challenges for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
